Zeev's Turnips - No Politics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Zeev's Turnips - No Politics

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: LTK007 who wrote (89065)	7/1/2002 2:24:12 PM
From: LTK007	of 99280

ALKS, whew, down 10.30 to 5.70 and ML AGAIN hits with a reduce/sell downgrade---another thing ML is doing, putting out sells <<14:05 ET Alkermes downgraded by Merrill -- more uncertainty (ALKS) 5.52 -10.49: --Update-- Merrill Lynch downgrades to REDUCE/SELL from Neutral after Risperdal Consta receives non-approvable letter. According to Merrill, the issues appear to be related to pre-clinical testing and not manufacturing. Firm finds FDA letter troubling as product represents ALKS's next major revenue opportunity. Also, decline in stock price raises concerns about the completion of the Reliant Pharma acquisition. Firm's earnings model remains the same pending further disclosure from ALKS.>> in the year 2000 only 2% of stocks had at least one sell rating on it. On PBS they had an analyst from the 60s. He said his work was 90% research and 10% putting out reports/ratings; and said on average only 30% of the companies he researched got a buy rating. Now he says analysts do 10% research, and 90% putting out reports and ratings---most all to buy.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next